Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, Competitive Analysis, Share, Forecast- 2020-2026

The global hypertrophic cardiomyopathy (HCM) therapeutics market is estimated to grow at a CAGR of nearly 1.5% during the forecast period. The significant prevalence of CVD is the major factor contributing to the market growth. As per the World Health Organization (WHO), CVDs are the major cause of mortality across the globe. In 2016, CVD accounted for nearly 17.9 million mortalities, which represented 31% of all global mortalities. 85% of these mortalities were reported due to stroke and heart attack. HCM is a genetic cardiac disease, which occurs due to the increase in wall thickness of left ventricle. It is usually caused by abnormal genes in the heart muscle, which cause left ventricle walls to become thicker and harder than normal.

Get Free Sample Copy @ https://www.omrglobal.com/request-sample/hypertrophic-cardiomyopathy-hcm-therapeutics-market

Each child of a person with HCM has a 50% chance of inheriting the condition. In UK, nearly 1 in 500 people have the condition, however, most people who are suffering from this condition have few symptoms. The objective of HCM treatment is to provide relief from symptoms and avoid sudden cardiac death in people who are at high risk. Medications can support to slow the heart rate that facilitates the heart to pump blood better. The medications that are used for the treatment of HCM and its symptoms may comprise calcium channel blockers, beta-blockers, antiarrhythmic drugs, and anticoagulants. However, these medications have certain side-effects that may comprise low blood pressure and fluid in the lungs and in some cases, certain medications may cause sudden death. The increasing demand for surgeries such as septal myectomy, septal ablation, heart transplant, and implantable cardioverter defibrillator, to treat HCM is further expected to hinder the market growth

Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/hypertrophic-cardiomyopathy-hcm-therapeutics-market

Market Segmentation

Global HCM Therapeutics Market by Drug Class

Beta Adrenergic Blocking Agents
Anticoagulants
Antiarrhythmic Agents
Calcium Channel Blockers
Others
Regional Analysis

North America

United States
Canada
Europe

UK
Germany
Italy
Spain
France
Rest of Europe
Asia-Pacific

China
India
Japan
Rest of Asia-Pacific
Rest of the World



Company Profiles

ANI Pharmaceuticals, Inc.
AstraZeneca plc
Bayer AG
Bristol Myers Squibb Co.
Cipla Ltd.
General Electric Co.
Gilead Sciences, Inc.
Lannett Co., Inc.
Merck & Co., Inc.
Mylan N.V.
MyoKardia, Inc.
Novartis International AG
Pfizer Inc.
Sanofi S.A.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/hypertrophic-cardiomyopathy-hcm-therapeutics-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.